Fairvalue-Calculator Fairvalue-Calculator
EN DE

Bioceltix S.A (BCX) Fair Value & Analysis

Healthcare · PL · Market cap 480M PLN

Price87.70 PLN
Fair Value59.60 PLN
Upside-32.0%
Quality95/100
Evidence: Low Range 44.70 PLN – 74.50 PLN

Fair value as of: Jun 24, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

Bioceltix S.A (BCX) currently trades at 87.70 PLN, while our model-based Fair Value estimate is 59.60 PLN — implying the stock looks roughly 32.0% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).

About the company

Bioceltix S.A. engages in the development of stem cell-based biopharmaceuticals for veterinary use. The company's products include BCX-CM-J, a stem-cell based biological drug for the treatment of osteoarthritis in dogs; BCX-CM-AD, a drug candidate based on allogeneic stem cells for the treatment of atopic dermatitis in dogs; and BCX-EM, a drug candidate based on allogeneic mesenchymal stem cells for the treatment of arthritis in horses. The company was founded in 2016 and is headquartered in Wroclaw, Poland.

Open the full interactive analysis →

Similar stocks

Vertex Pharmaceuticals Incorporated (VRTX34) -38% Regeneron Pharmaceuticals, Inc (REGN) -14% UCB SA (UCB) -28% argenx SE (ARGNF) -57% Samsung Biologics Co (207940) -28% Alnylam Pharmaceuticals, Inc (ALNY) -63%

Frequently asked questions

Is Bioceltix S.A (BCX) undervalued?
As of Jun 24, 2026, our model estimates a fair value of 59.60 PLN versus a price of 87.70 PLN — about −32% (overvalued). Model-based estimate, not financial advice.
What is the fair value of BCX?
Our 21-model fair value for Bioceltix S.A is 59.60 PLN (as of Jun 24, 2026), built from audited fundamentals. The current price is 87.70 PLN.
What is the quality score of BCX?
Bioceltix S.A has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.